KONTEATIS; Zenon D.
Patent Applications and Registrations
Patent applications and USPTO patent grants for KONTEATIS; Zenon D..The latest application filed is for "heterobicyclic inhibitors of mat2a and methods of use for treating cancer".
- KONTEATIS; Zenon D. - Cambridge MA
- KONTEATIS; Zenon D. - Chatham NJ
- Konteatis; Zenon D. - Chatham Twp NJ
- Konteatis; Zenon D. - Chatham Township NJ
- Konteatis; Zenon D. - South Orange NJ
| Patent | Date |
|---|---|
| Heterobicyclic Inhibitors Of Mat2a And Methods Of Use For Treating Cancer App 20220251081 - KONTEATIS; Zenon D. ; et al. | 2022-08-11 |
| New Organic Compounds App 20220169654 - KONTEATIS; Zenon D. ; et al. | 2022-06-02 |
| Aza-heterobicyclic Inhibitors Of Mat2a And Methods Of Use For Treating Cancer App 20220144820 - KONTEATIS; Zenon D. ; et al. | 2022-05-12 |
| Inhibitors of cellular metabolic processes Grant 11,325,914 - Konteatis , et al. May 10, 2 | 2022-05-10 |
| Aza-heterobicyclic Inhibitors Of Mat2a And Methods Of Use For Treating Cancer App 20220098203 - KONTEATIS; Zenon D. ; et al. | 2022-03-31 |
| Heterobicyclic Inhibitors Of Mat2a And Methods Of Use For Treating Cancer App 20210115045 - KONTEATIS; Zenon D. ; et al. | 2021-04-22 |
| Therapeutically active compounds and their methods of use Grant 10,946,023 - Konteatis , et al. March 16, 2 | 2021-03-16 |
| Inhibitors of cellular metabolic processes Grant 10,800,782 - Konteatis , et al. October 13, 2 | 2020-10-13 |
| 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer Grant 10,376,510 - Konteatis , et al. A | 2019-08-13 |
| Inhibitors Of Cellular Metabolic Processes App 20190233424 - Konteatis; Zenon D. ; et al. | 2019-08-01 |
| Inhibitors of cellular metabolic processes Grant 10,329,298 - Konteatis , et al. | 2019-06-25 |
| Therapeutically Active Compounds And Their Methods Of Use App 20190117661 - Konteatis; Zenon D. ; et al. | 2019-04-25 |
| Therapeutically active compounds and their methods of use Grant 10,172,864 - Konteatis , et al. J | 2019-01-08 |
| Therapeutically active compounds and their methods of use Grant 10,028,961 - Konteatis , et al. July 24, 2 | 2018-07-24 |
| Inhibitors Of Cellular Metabolic Processes App 20180079753 - Konteatis; Zenon D. ; et al. | 2018-03-22 |
| Therapeutically Active Compounds And Their Methods Of Use App 20170107194 - Konteatis; Zenon D. ; et al. | 2017-04-20 |
| Therapeutically active compounds and their methods of use Grant 9,579,324 - Konteatis , et al. February 28, 2 | 2017-02-28 |
| Therapeutically Active Compounds And Their Methods Of Use App 20160220572 - Konteatis; Zenon D. ; et al. | 2016-08-04 |
| 2,4- Or 4,6-diaminopyrimidine Compounds As Idh2 Mutants Inhibitors For The Treatment Of Cancer App 20160158230 - Konteatis; Zenon D. ; et al. | 2016-06-09 |
| Therapeutically Active Compounds And Their Methods Of Use App 20150018328 - Konteatis; Zenon D. ; et al. | 2015-01-15 |
| Urea inhibitors of MAP kinases Grant 7,741,479 - Michelotti , et al. June 22, 2 | 2010-06-22 |
| Substituted piperidines Grant 7,687,495 - Herold , et al. March 30, 2 | 2010-03-30 |
| 2,4,5-Substituted Piperidines as Renin Inhibitors App 20100029628 - Herold; Peter ; et al. | 2010-02-04 |
| Substituted piperidines App 20080171748 - Herold; Peter ; et al. | 2008-07-17 |
| Urea inhibitors of MAP kinases App 20060167247 - Michelotti; Enrique Luis ; et al. | 2006-07-27 |
| Pyrrolidine modulators of CCR5 chemokine receptor activity App 20020094989 - Hale, Jeffrey J. ; et al. | 2002-07-18 |
| Peptide skeletal muscle relaxants Grant 5,494,898 - Cheng , et al. February 27, 1 | 1996-02-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 